|Systematic (IUPAC) name|
|Mol. mass||248.235 g/mol|
Festinavir is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection. Festinavir is a nucleoside reverse transcriptase inhibitor that is active against HIV resistant to both abacavir and tenofovir, making the drug a candidate for people with multi-drug resistant (MDR) strains of the virus. Festinavir is a derivative of stavudine (d4T), but is less toxic. It was originally developed at Yale University.
- Alcorn, Keith (21 December 2010). "Bristol-Myers Squibb buys festinavir, new NRTI active against MDR HIV". aidsmap.com. aidsmap. Retrieved 24 June 2011.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|